Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EDIT NASDAQ:IMRX NASDAQ:PALI NASDAQ:TELO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$3.46+0.9%$2.88$1.66▼$4.54$335.82M2.142.48 million shs3.91 million shsIMRXImmuneering$5.77+14.0%$5.35$1.58▼$10.08$327.37M0.371.39 million shs2.93 million shsPALIPalisade Bio$2.12+2.9%$2.00$0.53▼$2.86$357.57M1.522.69 million shs751,895 shsTELOTelomir Pharmaceuticals$1.30+1.6%$1.31$1.05▼$3.10$88.03M-0.2189,240 shs128,283 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine-3.92%+28.46%+12.09%+55.91%+83.42%IMRXImmuneering-5.24%-3.07%-3.25%+1.40%+181.11%PALIPalisade Bio-0.48%+2.49%+5.64%+16.38%+169.11%TELOTelomir Pharmaceuticals-0.78%-1.54%-11.72%+0.79%-38.16%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEDITEditas Medicine$3.46+0.9%$2.88$1.66▼$4.54$335.82M2.142.48 million shs3.91 million shsIMRXImmuneering$5.77+14.0%$5.35$1.58▼$10.08$327.37M0.371.39 million shs2.93 million shsPALIPalisade Bio$2.12+2.9%$2.00$0.53▼$2.86$357.57M1.522.69 million shs751,895 shsTELOTelomir Pharmaceuticals$1.30+1.6%$1.31$1.05▼$3.10$88.03M-0.2189,240 shs128,283 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEDITEditas Medicine-3.92%+28.46%+12.09%+55.91%+83.42%IMRXImmuneering-5.24%-3.07%-3.25%+1.40%+181.11%PALIPalisade Bio-0.48%+2.49%+5.64%+16.38%+169.11%TELOTelomir Pharmaceuticals-0.78%-1.54%-11.72%+0.79%-38.16%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEDITEditas Medicine 2.57Moderate Buy$5.4056.07% UpsideIMRXImmuneering 2.86Moderate Buy$16.50185.96% UpsidePALIPalisade Bio 2.88Moderate Buy$10.20381.13% UpsideTELOTelomir Pharmaceuticals 2.00HoldN/AN/ACurrent Analyst Ratings BreakdownLatest TELO, EDIT, PALI, and IMRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2026EDITEditas Medicine TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/19/2026IMRXImmuneering Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.005/5/2026EDITEditas Medicine Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$3.50 ➝ $4.004/21/2026TELOTelomir Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/20/2026EDITEditas Medicine Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)4/9/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.004/8/2026PALIPalisade Bio Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$7.003/27/2026IMRXImmuneering Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)3/26/2026PALIPalisade Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.003/18/2026TELOTelomir Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold3/10/2026EDITEditas Medicine JonesTradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$8.00(Data available from 5/29/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEDITEditas Medicine$38.69M8.75N/AN/A$0.05 per share69.20IMRXImmuneeringN/AN/AN/AN/A$3.19 per shareN/APALIPalisade Bio$250K1,471.96N/AN/A$0.73 per share2.90TELOTelomir PharmaceuticalsN/AN/AN/AN/A$0.07 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEDITEditas Medicine-$160.06M-$1.23N/AN/AN/A-281.59%-677.39%-58.25%8/11/2026 (Estimated)IMRXImmuneering-$56.03M-$1.17N/AN/AN/AN/A-31.93%-29.92%8/12/2026 (Estimated)PALIPalisade Bio-$16.78M-$1.01N/AN/AN/AN/A-36.79%-34.34%8/10/2026 (Estimated)TELOTelomir Pharmaceuticals-$10.41M-$0.29N/AN/AN/AN/A-201.23%-172.71%N/ALatest TELO, EDIT, PALI, and IMRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2026Q1 2026IMRXImmuneering-$0.30-$0.21+$0.09-$0.21N/AN/A5/14/2026Q1 2026TELOTelomir Pharmaceuticals-$0.07-$0.03+$0.04-$0.03N/AN/A5/12/2026Q1 2026PALIPalisade Bio-$0.04-$0.05-$0.01-$0.05N/AN/A5/5/2026Q1 2026EDITEditas Medicine-$0.30-$0.26+$0.04-$0.26$6.37 million$2.83 million3/17/2026Q4 2025TELOTelomir Pharmaceuticals-$0.07-$0.06+$0.01-$0.06N/AN/A3/9/2026Q4 2025EDITEditas Medicine-$0.27-$0.06+$0.21-$0.06$8.77 million$24.74 million3/6/2026Q4 2025IMRXImmuneering-$0.31-$0.18+$0.13-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEDITEditas MedicineN/AN/AN/AN/AN/AIMRXImmuneeringN/AN/AN/AN/AN/APALIPalisade BioN/AN/AN/AN/AN/ATELOTelomir PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEDITEditas MedicineN/A3.223.22IMRXImmuneeringN/A32.4532.45PALIPalisade BioN/A23.7123.71TELOTelomir PharmaceuticalsN/A7.007.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEDITEditas Medicine71.90%IMRXImmuneering67.65%PALIPalisade Bio11.79%TELOTelomir PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipEDITEditas Medicine3.10%IMRXImmuneering22.90%PALIPalisade Bio0.07%TELOTelomir PharmaceuticalsN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEDITEditas Medicine23097.91 million94.87 millionOptionableIMRXImmuneering6064.70 million49.88 millionNot OptionablePALIPalisade Bio10173.58 million173.46 millionNot OptionableTELOTelomir Pharmaceuticals168.78 millionN/AN/ATELO, EDIT, PALI, and IMRX HeadlinesRecent News About These CompaniesTelomir Pharmaceuticals Inc TELOMay 26 at 7:36 PM | morningstar.comMTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson’s DiseaseMay 20, 2026 | usatoday.comTelomir-Zn Preclinical Data Published in Wilson’s DiseaseMay 20, 2026 | tipranks.comTelomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's DiseaseMay 20, 2026 | accessnewswire.comATelomir Pharmaceuticals Receives FDA IND Clearance for Telomir-ZnApril 30, 2026 | tipranks.comTelomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast CancerApril 30, 2026 | accessnewswire.comATelomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)April 24, 2026 | usatoday.comTelomir Pharmaceuticals Inc.April 2, 2026 | barrons.comTelomir seeks FDA approval for Telomir-1 to treat breast cancerApril 2, 2026 | msn.comTelomir Pharmaceuticals Regains Nasdaq Listing Rule ComplianceMarch 31, 2026 | tipranks.comTelomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast CancerMarch 31, 2026 | accessnewswire.comATelomir Shareholders Approve Equity Plan and Bylaw ChangesMarch 27, 2026 | tipranks.comTelomir Pharmaceuticals Faces Crucial Corporate and Regulatory DeadlinesFebruary 21, 2026 | aktiencheck.deATelomir Sets Vote on Transformative TELI Merger and Governance ChangesFebruary 19, 2026 | tipranks.comTelomir reveals promising preclinical data for Telomir-ZnFebruary 17, 2026 | tipranks.comTelomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer ModelsFebruary 17, 2026 | accessnewswire.comATelomir Pharmaceuticals Highlights Preclinical Data for Telomir-1February 5, 2026 | tipranks.comTelomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and AgingFebruary 5, 2026 | accessnewswire.comAFinancial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR)January 18, 2026 | defenseworld.netDTelomir Highlights Positive Preclinical Results for Telomir-1 in TNBCJanuary 5, 2026 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAs Broadcom Eclipses $2 Trillion, Private Credit Giants Wants InBy Leo Miller | May 17, 2026Viking Sails to All-Time Highs—Fundamentals Signal More to ComeBy Chris Markoch | May 15, 2026CAVA Group’s Stock Looks Delicious After Strong EarningsBy Chris Markoch | May 22, 2026AI Demand Fuels Strong Q1 Earnings for Constellation EnergyBy Chris Markoch | May 12, 2026NerdWallet’s Growth Story Looks Strong—But Can It Last?By Peter Frank | April 30, 2026TELO, EDIT, PALI, and IMRX Company DescriptionsEditas Medicine NASDAQ:EDIT$3.46 +0.03 (+0.87%) Closing price 04:00 PM EasternExtended Trading$3.44 -0.02 (-0.72%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.Immuneering NASDAQ:IMRX$5.77 +0.71 (+14.03%) Closing price 04:00 PM EasternExtended Trading$5.83 +0.06 (+1.04%) As of 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.Palisade Bio NASDAQ:PALI$2.12 +0.06 (+2.91%) Closing price 04:00 PM EasternExtended Trading$2.11 -0.01 (-0.28%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.Telomir Pharmaceuticals NASDAQ:TELO$1.30 +0.02 (+1.56%) Closing price 04:00 PM EasternExtended Trading$1.32 +0.02 (+1.23%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022. Telomir Pharmaceuticals, Inc. was incorporated in 2021 and is headquartered in Baltimore, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Shares Fall, Targets Rise—Markets and Analysts Diverge on Synopsys Dollar Tree Keeps Winning After Family Dollar Divorce Salesforce Stock Finds Support as AI Momentum Builds Marvell’s Pullback May Be the Setup Bulls Were Waiting For Snowflake and the Snowballing Impact of its AI Flywheel China Deal Ignites Boeing's Financial Afterburners IREN Is Flipping the Switch from Bitcoin to AI Flight Path to Profits: American Airlines Bets on SpaceX Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
